California Stem-Cell Agency Gets Off to Inauspicious Start
By David P. Hamilton,
The Wall Street Journal
| 07. 05. 2005
AS POLITICIANS in Washington tussle over a bill that could expand federal funding for embryonic stem-cell research, California's newly minted $3 billion commitment to the field is still trying to get itself off the ground.
Eight months after a state ballot initiative, Proposition 71, established the California Institute for Regenerative Medicine, the stem-cell agency's main accomplishment has been to bootstrap itself into existence.
The institute has staked out a new permanent headquarters site in San Francisco, selected an interim president and put together several panels of experts to help evaluate funding requests and determine research standards. But its real mission -- to funnel roughly $300 million a year into California-based stem-cell research and facilities over the next decade -- is stalled.
see moreThanks to a lawsuit that has delayed a planned sale of state bonds, the institute's main source of funding is in limbo. The stem-cell agency has been subsisting on an initial loan from the state and couldn't even hire additional support staff until philanthropists offered it a $5 million gift earlier this month. In the meantime, it has been...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...